title: [Effects of shexiang baoxin pill on angiogenesis in atherosclerosis plaque and ischemic myocardium].
abstract: OBJECTIVE
  To investigate the effects of Shexiang Baoxin Pill (SBP) in intervening atherosclerosis and myocardial infarction (AS-MI) in experimental animals, and inspect its influences on angiogenesis.
  
  
  METHODS
  Twenty male New-Zealand rabbits were made into AS-MI model, and randomly divided into 2 groups equally. Group A was fed with high-fat diet for control; Group B was fed with high-fat diet but intervened with SBP. The cardiac function and the positive area of plaque were determined. The CD34 positive response intensity at infarcted marginal zone and aorta vessel wall, and the capillary density of myocardium were measured by immunohistochemical staining. In addition, the protein expressions of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2) were detected by Western blot.
  
  
  RESULTS
  Compared to Group A, the cardiac function was obviously improved (P<0.05) and the plaque positive area (%) was significantly decreased in Group B (45.82 +/- 3.68 vs 82.56 +/- 4.97, P<0.01). The CD34 positive response intensity and the capillary density as well as VEGF and VEGFR-2 expressions in infarcted marginal zone in Group A were higher than those in Group B (P<0.01); but these parameters at aorta vessel walls were lower in Group A than in Group B (P<0.01).
  
  
  CONCLUSIONS
  SBP could advance the angiogenesis in the marginal zone of infarction, improve heart function, and embarrass angiogenesis in atherosclerotic plaque.
authors.affiliation: Department of Cardiology, Huashan Hospital, Fundan University, Shanghai 200040.
authors.forename: Wei
authors.initials: W
authors.lastname: Shen
authors.forename: Wei-hu
authors.initials: WH
authors.lastname: Fan
authors.forename: Hai-ming
authors.initials: HM
authors.lastname: Shi
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000503:physiopathology*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D008297:Male; D017202:Myocardial Ischemia / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000503:physiopathology / Q000517:prevention & control*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D058226:Plaque, Atherosclerotic / Q000473:pathology / Q000503:physiopathology; D011817:Rabbits; D011897:Random Allocation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism
chemical_list: D004365:Drugs, Chinese Herbal; D042461:Vascular Endothelial Growth Factor A; C526712:shexiang baoxin; D040301:Vascular Endothelial Growth Factor Receptor-2